Schizophrenia research in 2026: report from the annual meeting of the Schizophrenia International Research Society

Abstract SIRS 2026, held under the theme “Schizophrenia Research in the Era of Artificial Intelligence,” brought together researchers, clinicians, and persons with lived experience to take stock of a field whose tools for measuring, predicting, and intervening in psychosis have expanded rapidly. Themes spanned artificial intelligence, automated speech analysis, retinal imaging, computational modelling, and novel psychosocial and pharmacological targets, with evidence that, individually, warrants cautious but serious attention and that, collectively, points toward a more mechanistically grounded psychiatry. A recurring call across the meeting was for rigorous external validation, equitable implementation, and sustained scrutiny of underlying assumptions, including whether existing diagnostic categories and treatment targets remain adequate. Some areas remained underworked relative to their importance, including translating basic neuroscience advances into questions relevant to patients and families, and the structural determinants of illness onset and treatment access. Perhaps the most significant development at SIRS 2026 was not any single scientific finding but the broadening of whose voices and experiences are treated as evidence worth taking seriously in this era of AI, a shift whose consolidation remains a question for the field as much as for any individual programme of work.

Authors

Institutions

Publication Details

Journal
Schizophrenia
Published
2026-10-16
DOI
https://doi.org/10.1038/s41537-026-00813-3
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Schizophrenia research in 2026: report from the annual meeting of the Schizophrenia International Research Society

Patricio Carvajal-Paredes, Erik Vélez-Pérez, Zhiqian Fang, Sean Halstead et al.
Schizophrenia
Schizophrenia research and treatment
article

Schizophrenia research in 2026: report from the annual meeting of the Schizophrenia International Research Society

Patricio Carvajal-Paredes, Erik Vélez-Pérez, Zhiqian Fang, Sean Halstead, Merel Koster, Burcu Verim, Yuji Yamada, Mylène Moyal, Federica Iannotta, Ramon Reis, Pavo Orepić, Fernando Gonzales-Aste, Catherine V. Barnes-Scheufler, Alessandra Martinelli, Zui C. Narita, Upasana Ravinder, Giuseppe De Simone, Pierfrancesco Sarti, Kristoffer J. Panganiban, Lawrence Kin-hei Chung, Mathilde Parisi, Rafaella Ormond, Samantha Johnstone, Gisela Mezquida, Yohannes Gebreegziabhere Haile, Merridee J. Lefner, Soyolsaikhan Odkhuu, Pedro Henrique Destro, Àlex G. Segura, Elif Sarisik, Mohammed Alarabi, Alban Voppel, Boutheina Abassi, Anson Kai Chun Chau, Franciska de Beer, Camila Marcelino Loureiro, Lena K. Palaniyappan, Xuemei Ma, Annkathrin Böke, Rui He, Berat Arslan, María Ortuño, Jennifer Murphy, Abigail L Gee, Qian Ren, Chaimaa El Mouslih, Pedro Henrique Minotto Serafim, Mona Dlikan, In‐Kyung Park, Linda Bryant, G. Pezzullo, Seo Ho Song, Héctor Hernández-Ruiz, Fatme Abboud, Maite Aramburu, Santiago Castiello de Obeso, Finn Rabe
article en

Abstract

Abstract SIRS 2026, held under the theme “Schizophrenia Research in the Era of Artificial Intelligence,” brought together researchers, clinicians, and persons with lived experience to take stock of a field whose tools for measuring, predicting, and intervening in psychosis have expanded rapidly. Themes spanned artificial intelligence, automated speech analysis, retinal imaging, computational modelling, and novel psychosocial and pharmacological targets, with evidence that, individually, warrants cautious but serious attention and that, collectively, points toward a more mechanistically grounded psychiatry. A recurring call across the meeting was for rigorous external validation, equitable implementation, and sustained scrutiny of underlying assumptions, including whether existing diagnostic categories and treatment targets remain adequate. Some areas remained underworked relative to their importance, including translating basic neuroscience advances into questions relevant to patients and families, and the structural determinants of illness onset and treatment access. Perhaps the most significant development at SIRS 2026 was not any single scientific finding but the broadening of whose voices and experiences are treated as evidence worth taking seriously in this era of AI, a shift whose consolidation remains a question for the field as much as for any individual programme of work.

Schizophrenia
Goethe University Frankfurt (DE), Western University (CA), Debre Berhan University (ET), Montreal Neurological Institute and Hospital (CA), Queensland Health (AU), Universidade Federal do Rio Grande do Sul (BR), Beth Israel Deaconess Medical Center (US), University Medical Center Groningen (NL), Centre for Addiction and Mental Health (CA), Harvard University (US), Seoul National University (KR), Royal College of Surgeons in Ireland (IE), Consejo Nacional de Investigaciones Científicas y Técnicas (AR), Inserm (FR), Pontificia Universidad Católica de Chile (CL), Ponce Health Sciences University (PR), The University of Queensland (AU), Oregon Health & Science University (US), University of Groningen (NL), Universitat Pompeu Fabra (ES), Chinese University of Hong Kong (HK), Universidade de São Paulo (BR), University of Cologne (DE), King's College London (GB), University of Toronto (CA), Dokuz Eylül University (TR), Chinese Academy of Sciences (CN), University of Zurich (CH), Douglas Mental Health University Institute (CA), Instituto de Salud Carlos III (ES), King Saud University (SA), New Generation University College (ET), Amsterdam UMC Location University of Amsterdam (NL), Pontificia Universidad Católica Argentina (AR), Yale University (US), Centro de Investigación Biomédica en Red de Salud Mental (ES), University Hospital of Zurich (CH), Vall d'Hebron Institut de Recerca (ES), National Center of Neurology and Psychiatry (JP), Centro San Giovanni di Dio Fatebenefratelli (IT), Hospital Clínic de Barcelona (ES), Institut de Psychiatrie et Neurosciences de Paris (FR), Institute of Psychology, Chinese Academy of Sciences (CN), University Hospital Frankfurt (DE), Max Planck Institute of Psychiatry (DE), University Hospital Cologne (DE), Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (MX), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), National Institute of Mental Health (JP), Hôpital Razi de La Manouba (TN), Faculté de médecine de Tunis, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES), Psychiatrische Universitätsklinik Zürich (CH), National Center Hospital of Neurology and Psychiatry (JP), McGill University (CA), Universitat Rovira i Virgili (ES), University at Buffalo, State University of New York (US), Tunis El Manar University (TN), National Institute of Mental Health and Neurosciences (IN), University of Naples Federico II (IT), Universitat de Barcelona (ES), Jeonbuk National University (KR), Universidade Federal de São Paulo (BR), University of Hong Kong (HK)
Fonds de Recherche du Québec - Santé
Good health and well-being
Openalex Percentile: Top 13%
Schizophrenia research and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.